Clinical Trial Update: A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating JNJ-64041809 in combination with apalutamide versus apalutamide for metastatic castration-resistant prostate cancer has been withdraw…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• ERLEADA (apalutamide)
• JNJ-64041809 (Listeria monocytogenes-based live attenuated immunotherapy)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Prostatic Neoplasms, Castration-Resistant | Phase 2 | Status: WITHDRAWN